Nektar Therapeutics reported $7.23M in Interest Expense on Debt for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
ALKERMES ALKS:US 2.37M 19K
Amgen AMGN:US $ 328M 33M
Baxter International BAX:US $ 93M 5M
Biocryst Pharmaceuticals BCRX:US $ 24.02M 0.18M
Biogen BIIB:US $ 65.8M 0.3M
Bristol Myers Squibb BMY:US $ 313M 13M
Eli Lilly And LLY:US $ 81.2M 3.7M
Esperion Therapeutics ESPR:US $ 14.27M 204K
Gilead Sciences GILD:US $ 242M 4M
Halozyme Therapeutics HALO:US $ 3.1M 1.34M
Immunogen IMGN:US $ 1.08M 0.17M
IONIS PHARMACEUT IONS:US $ 2.13M 0.01M
Ironwood Pharmaceuticals IRWD:US $ 2.21M 0.13M
Karyopharm Therapeutics KPTI:US $ 6.31M 371K
Nektar Therapeutics NKTR:US $ 7.23M 0.3M
Neurocrine Biosciences NBIX:US $ 2.2M 0.4M
Novartis NOVN:VX 202M 1000K
Pfizer PFE:US $ 293M 29M
Sarepta Therapeutics SRPT:US $ 16.03M 0.23M
Teva Pharmaceutical TEVA:IT 225M 13M
YTE INCY:US $ 0.68M 0M